111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Friday,Weiss Ratings reports.
111 Price Performance
YI stock opened at $6.93 on Friday. The stock has a market capitalization of $59.88 million, a PE ratio of -10.83 and a beta of 0.47. The company's 50-day moving average is $8.00 and its 200-day moving average is $7.55. 111 has a 1 year low of $4.15 and a 1 year high of $12.90.
111 (NASDAQ:YI - Get Free Report) last released its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $486.35 million for the quarter.
Hedge Funds Weigh In On 111
Several large investors have recently added to or reduced their stakes in the business. FIL Ltd purchased a new stake in 111 in the 4th quarter valued at about $450,000. Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in shares of 111 during the 4th quarter worth approximately $245,000. JPMorgan Chase & Co. increased its stake in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after purchasing an additional 305,339 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of 111 during the 1st quarter worth approximately $92,000. Finally, Deuterium Capital Management LLC purchased a new stake in shares of 111 during the 1st quarter worth approximately $81,000. Institutional investors own 21.32% of the company's stock.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
